Skip to content

Pharminent

cropped-neurology_aaic_banner_frontpage_2026-07-15-1.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Pipeline
  • Chasing Dupixent, a biotech aims to make better antibody drugs for eczema
  • Pipeline

Chasing Dupixent, a biotech aims to make better antibody drugs for eczema

BioPharma Dive

Infinimmune, a California startup, is developing treatments it claims might last longer and be more effective than existing atopic dermatitis medications.

Immunology & Inflammation

Read full story

pharminent August 11, 2026 (Last updated: August 11, 2026)

BioPharma Dive

Infinimmune, a California startup, is developing treatments it claims might last longer and be more effective than existing atopic dermatitis medications.

Immunology & Inflammation

Read full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: BMS banks on Texas for $2.3bn multi-modal manufacturing facility
Next: Trump Executive Order Strips Seven Vaccines From Childhood Immunization Recommendations

Related Stories

  • Pipeline

BioMarin axes asset from $270M Inozyme takeover, ending run in rare metabolic indication

pharminent August 10, 2026
  • Pipeline

Gilead looks to upcoming inflammation, cancer catalysts as pressure to diversify mounts

pharminent August 5, 2026
  • Pipeline

Sanofi drops two more programmes in R&D clear-out

pharminent July 30, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.